Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial

These flashcards cover key terminology and concepts from the trial of maridebart cafraglutide for obesity treatment, intended to assist in exam preparation.

Maridebart Cafraglutide

A long-acting peptide–antibody conjugate intended for the treatment of obesity, combining GLP-1 receptor agonism and GIP receptor antagonism.

Placebo-controlled trial

A study where one group receives the experimental treatment while another group receives an inactive treatment, allowing comparison of outcomes.

Glycated hemoglobin (HbA1c)

A form of hemoglobin that is chemically linked to a sugar; used to measure long-term glucose levels in the blood.

Adverse events

Unfavorable or unintended outcomes occurring during or after treatment, used to assess the safety profile of a medication.

Intention-to-treat analysis

An analysis that includes all participants as randomized, regardless of whether they completed the study or adhered to the treatment protocol.